Objective
to compare the clinical safety and efficacy of polymer-free amphilimus-eluting stents (PF-AES) with permanent-polymer zotarolimus-eluting stents (PP-ZES)
Study
physician-initiated, prospective multicentre, randomised non-inferiority trial (1:1; margin 3.5%)
Population
all-comers
Endpoints
target lesion failure as cardiac death, target-vessel MI or target-lesion revascularisation at 12 months
Conclusion
PF-AES is non-inferior to PP-ZES in treating all-comers at 12 months
Rozemeijer et al. Circulation. 2019;139:67-77
